| 吡格列酮对2型糖尿病患者血清脂联素、内脂素水平的影响 |
| |
| 引用本文： | 汤佳珍,杨治芳,甘华侠,刘建英,章燕.吡格列酮对2型糖尿病患者血清脂联素、内脂素水平的影响[J].矿产勘查,2011(3):19-21. |
| |
| 作者姓名： | 汤佳珍 杨治芳 甘华侠 刘建英 章燕 |
| |
| 作者单位： | 南昌大学第一附属医院内分泌科,南昌330006 |
| |
| 基金项目： | 江西省卫生厅普通科技计划（20061029） |
| |
| 摘 要： | 目的观察吡格列酮对2型糖尿病（T2DM）患者血清脂联素、内脂素的影响。方法对新诊断的49例T2DM患者（T2DM组）和50例健康体检者（对照组）采用病例对照及治疗前后自身对照的方法,比较2组治疗前及T2DM组经吡格列酮治疗12周后空腹血清脂联素、内脂素的水平。结果 T2DM组治疗前与对照组相比,脂联素水平下降（6.4±1.1）mg·L^-1vs（12.3±2.8）mg·L^-1,P〈0.01],内脂素水平升高（36.2±10.6）μg·L^-1vs（13.5±9.2）μg·L^-1,P〈0.01];治疗后T2DM组与治疗前比较,脂联素明显升高（9.1±1.4）mg·L^-1vs（6.4±1.1）mg·L^-1,P〈0.05],而内脂素无明显变化（34.5±11.4）μg·L^-1vs（36.2±10.6）μg·L^-1,fquP〉0.05]。结论吡格列酮治疗可改善T2DM所导致的脂联素水平改变,而对内脂素水平无明显影响。
|
| 关 键 词： | 2型糖尿病 吡格列酮 脂联素 内脂素 |
Effects of Pioglitazone on Serum Adiponectin and Visfatin Levels in Patients with Type 2 Diabetes Mellitus |
| |
| TANG Jia-zhen,YANG Zhi-fang,GAN Hua-xia,LIU Jian-ying,ZHANG Yan.Effects of Pioglitazone on Serum Adiponectin and Visfatin Levels in Patients with Type 2 Diabetes Mellitus[J].Mineral Exploration,2011(3):19-21. |
| |
| Authors: | TANG Jia-zhen YANG Zhi-fang GAN Hua-xia LIU Jian-ying ZHANG Yan |
| |
| Affiliation: | (Department of Endocrinology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China) |
| |
| Abstract: | Objective To investigate the effects of pioglitazone on fasting serum adiponectin and visfatin levels in patients with type 2 diabetes mellitus（T2DM）.Methods A case-control and a self-controlled study were conducted in 49 patients with newly diagnosed T2DM（T2DM group） and 50 healthy subjects（normal control group）.Fasting serum adiponectin and visfatin levels were compared between the two groups,and the changes in the levels were measured after treatment with pioglitazone for 12 weeks.Results Compared with normal control group,pioglitazone induced a decrease in fasting serum levels of adiponectin and an increase in levels of visfatin （12.3±2.8）mg·L^-1 vs（6.4±1.1）mg·L^-1] and （13.5±9.2）μg·L^-1 vs（36.2±10.6） μg·L^-1],（P0.01）.Compared with the levels before treatment,adiponectin levels markedly increased 12 weeks after treatment with pioglitazone （9.1±1.4）mg·L^-1 vs（6.4±1.1）mg·L^-1,P0.05],but no changes in visfatin levels were observed （34.5 ±11.4）μg·L^-1 vs（36.2±10.6）μg·L^-1,P0.05].Conclusion Pioglitazone can improve the decrease in serum adiponectin levels,but has no impact on the levels of serum visfatin in patients with T2DM. |
| |
| Keywords: | type 2 diabetes mellitus pioglitazone adiponectin visfatin |
| 本文献已被 维普 等数据库收录！ |
|
